# Hangzhou Tengdi Biomedical Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-tengdi-biomedical-technology

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Total disclosed funding: $3.3M
- Latest round: Seed (Dec 17, 2021)
- Investors on record: 1

## About

Established in 2021 and based in Hangzhou, China, Hangzhou Tengdi Biomedical Technology is a biopharmaceutical company that focuses on AI-assisted design of new protein drug research and development. In December 2021, the company raised USD 3.3 million in seed funding from new investor. The company founder and CEO Dr. Mingfu Zhu is the assistant professor of bioinformatics at Duke University School of Medicine.

The company's main business is AI-assisted research, development and design of new protein drug.

The company plan to use the seed funding for expand the team and establish a protein drug design and screening platform.

## Funding rounds

- Seed, Dec 17, 2021, $3.3M — BlueRun Ventures

## Investors

- BlueRun Ventures (https://capitalatlas.ai/funds/bluerun-ventures) — Seed